Combination of peripheral blood gene expression profiles and clinical parameters predicts response for tocilizumab (anti-IL6) treatment in rheumatoid arthritis
Peripheral blood samples were obtained at week 0 and week 4 of tocilizumab treatment and global gene expression profiling identified markers of responder status.
- Primary Purpose
- -
- Description of Cohorts
- -
- Informed Consent Given?
- -
- Multi-center Study?
- -
- Organisms
- Homo sapiens
- Number of subjects
- -
- Diseases
- rheumatoid arthritis
- Sample Sources
- -
- Type of Samples Collected
- -